Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Cools

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Acta Cardiologica|October 30, 2018
Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registryFrank Cools, Bart Wollaert, Geert Vervoort, et al.
The Lancet. Haematology|July 2, 2022
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trialFrank Cools, Saverio Virdone, Jitendra Sawhney, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
Heart (British Cardiac Society)|September 21, 2016
Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillationA John Camm, Gabriele Accetta, Giuseppe Ambrosio, et al.
Acta Cardiologica|January 7, 2021
Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe studyTim A C de Vries, Martin E W Hemels, Frank Cools, et al.
American Heart Journal|May 26, 2019
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AFSylvia Haas, A John Camm, Jean-Pierre Bassand, et al.
Future Cardiology|July 23, 2020
GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of strokeJean-Pierre Bassand, Patricia N Apenteng, Dan Atar, et al.
Journal of Thrombosis and Haemostasis : JTH|September 4, 2020
Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registryJaap Seelig, Martin E W Hemels, Olivier Xhaët, et al.
The New England Journal of Medicine|July 26, 2011
Apixaban with antiplatelet therapy after acute coronary syndromeJohn H Alexander, Renato D Lopes, Stefan James, et al.
Thrombosis Research|August 25, 2023
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trialsStefano Barco, Saverio Virdone, Andrea Götschi, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Acta Cardiologica|October 30, 2018
Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registryFrank Cools, Bart Wollaert, Geert Vervoort, et al.
The Lancet. Haematology|July 2, 2022
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trialFrank Cools, Saverio Virdone, Jitendra Sawhney, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
Heart (British Cardiac Society)|September 21, 2016
Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillationA John Camm, Gabriele Accetta, Giuseppe Ambrosio, et al.
Acta Cardiologica|January 7, 2021
Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe studyTim A C de Vries, Martin E W Hemels, Frank Cools, et al.
American Heart Journal|May 26, 2019
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AFSylvia Haas, A John Camm, Jean-Pierre Bassand, et al.
Future Cardiology|July 23, 2020
GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of strokeJean-Pierre Bassand, Patricia N Apenteng, Dan Atar, et al.
Journal of Thrombosis and Haemostasis : JTH|September 4, 2020
Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registryJaap Seelig, Martin E W Hemels, Olivier Xhaët, et al.
The New England Journal of Medicine|July 26, 2011
Apixaban with antiplatelet therapy after acute coronary syndromeJohn H Alexander, Renato D Lopes, Stefan James, et al.
Thrombosis Research|August 25, 2023
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trialsStefano Barco, Saverio Virdone, Andrea Götschi, et al.
Pageof 4